Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells + platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Liaocheng City People's Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intradermal, Topical
01
Overview
This investigational cell therapy is a combination of human umbilical cord-derived mesenchymal stem cells (huMSCs) and platelet-rich plasma (PRP), developed by Liaocheng People's Hospital for the treatment of stage 3 and 4 pressure injuries. The huMSCs are clinical-grade cells derived from Wharton's jelly and produced under Good Manufacturing Practice (GMP) conditions. The treatment regimen involves intradermal injection of the huMSC-PRP mixture into the ulcer margins and bottom, followed by the topical application of an autologous PRP gel. The therapy works through multiple regenerative mechanisms, including the promotion of re-epithelialization, stimulation of angiogenesis, and enhancement of granulation tissue formation to accelerate the healing of deep pressure ulcers. The cells used in this therapy have been certified by the National Institutes for Food and Drug Control of China.
- Other names
- hUC-MSCshuMSCsPRP combined with huMSCshuman umbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells + platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells + platelet-rich plasma.